Koutsilieris M, Lembessis P, Luu-The V, Sourla A
Department of Experimental Physiology, Medical School, University of Athens, Greece.
Clin Exp Metastasis. 1999;17(10):823-30. doi: 10.1023/a:1006783330996.
We performed repetitive molecular staging using, nested rt-PCR for PSA and PSM at the peripheral blood (PB) and bone marrow (BM) of patients with prostate cancer (Pr.Ca) and benign prostate hyperplasia (BPH) after transrectal ultrasonography-guided biopsy (TRUS-B; 6-9 biopsies/patient), Pr.Ca patients after radical prostatectomy (RP), and Pr.Ca patients with diffuse bony metastases. All BPH patients (N = 20) tested negative at BM. Of the 2 who tested positive at PB 2 weeks after TRUS-B tested negative 8 weeks after TRUS-B. Of the 17 Pr.Ca, 7 (41.2%) tested positive at PB for PSA and PSM 2 weeks after TRUS-B while only 4 (23.5%) of them tested positive at repetitive analysis 8 weeks after TRUS-B. Two (11.8%) of the 17 Pr.Ca patients had positive analysis at BM for PSA and PSM 2 and 8 weeks after TRUS-B. Of 12 Pr.Ca patients with negative pre-operative molecular staging, 7 (58.3%) tested positive at PB for PSA and PSM 2 months post-RP but only 3 (25%) of them re-tested positive 12 months post-RP. Of these 12 Pr.Ca, 4 (33.3%) tested positive at BM for PSA and PSM 2 months post-RP while none re-tested positive 12 months post-RP. All Pr.Ca (N = 20) with diffuse bony lesions tested positive at BM. At PB, 6 of them (30%) tested negative for both PSA and PSM. Our data suggest that nested rt-PCR for PSA and PSM at PB is affected by TRUS-B and RP, while such analysis at BM concerted diffuse bony disease.
我们采用巢式逆转录聚合酶链反应（nested rt-PCR），对前列腺癌（Pr.Ca）和良性前列腺增生（BPH）患者经直肠超声引导下活检（TRUS-B；每位患者6-9次活检）后外周血（PB）和骨髓（BM）中的前列腺特异性抗原（PSA）和前列腺特异性膜抗原（PSM）进行重复分子分期，还对前列腺癌根治术后（RP）的Pr.Ca患者以及有弥漫性骨转移的Pr.Ca患者进行了检测。所有BPH患者（N = 20）骨髓检测均为阴性。TRUS-B后2周外周血检测呈阳性的2例患者，在TRUS-B后8周检测为阴性。17例Pr.Ca患者中，7例（41.2%）在TRUS-B后2周外周血PSA和PSM检测呈阳性，而在TRUS-B后8周重复检测时，只有4例（23.5%）呈阳性。17例Pr.Ca患者中有2例（11.8%）在TRUS-B后2周和8周骨髓PSA和PSM检测呈阳性。12例术前分子分期为阴性的Pr.Ca患者中，7例（58.3%）在RP后2个月外周血PSA和PSM检测呈阳性，但在RP后12个月重新检测时，只有3例（25%）仍为阳性。这12例Pr.Ca患者中，4例（33.3%）在RP后2个月骨髓PSA和PSM检测呈阳性，而在RP后12个月重新检测时均为阴性。所有有弥漫性骨病变的Pr.Ca患者（N = 20）骨髓检测均为阳性。在外周血中，其中6例（30%）PSA和PSM检测均为阴性。我们的数据表明，外周血中PSA和PSM的巢式rt-PCR受TRUS-B和RP影响，而骨髓中的此类分析与弥漫性骨病相关。
